N-Nitrosodibenzylamine (NDBzA) is a contaminant found frequently in rubber baby bottle nipples and pacifiers. To evaluate more fully the mutagenic potential and analyse the molecular nature of possible mutations induced in vivo, we have studied the mutagenicity of NDBzA in vivo using the Muta™Mouse system. NDBzA, suspended in olive oil, was administered orally once to male mice at different doses (0, 30, 100, 425 and 750 mg/kg) and the mice were killed 30 and 90 days after treatment. As a positive control, and to compare relative mutagenicity, N-nitrosodimethylamine (NDMA) was also administered to animals in the same experiment at doses of 0, 2, 6 and 10 mg/kg. Mutant frequencies were increased in both 30 and 90 day liver samples, but not in bone marrow, after both NDBzA and NDMA treatment. However, NDBzA was Ͼ100 times less mutagenic than NDMA. A total of 81 mutants obtained from liver samples of treated animals (750 mg/kg) were characterized by DNA sequencing. While spontaneous mutations in transgenic mice have been characterized previously by a preponderance of G:C→A:T transitions, mainly at 5Ј-CpG-3Ј dinucleotide sites, the predominant type of NDBzA-induced mutation in this study was transversion, mainly G:C→T:A changes. The molecular characteristics of mutations induced by NDBzA indicate that they may arise from specific unidentified DNA adducts and benzylation appears to be the primary mechanism involved in formation of these DNA adducts.
Introduction
N-Nitrosodibenzylamine (NDBzA*), a semi-volatile aromatic nitrosamine, has been detected as a contaminant in rubber products, including baby bottle nipples and pacifiers (1) , and in some meat products packaged in reformulated rubber netting (2) (3) (4) . It is structurally related to other strongly mutagenic nitrosamines, such as N-nitrosodimethylamine (NDMA), but is considered to be more lipophilic (1) . Although the extent of human exposure to NDBzA is not known, its presence, together with other nitrosamines, in these products has been considered a potential human health hazard (5, 6) .
Studies of the carcinogenic potential of NDBzA are inconclusive. Although it has been reported to be a non-carcinogen in an early study in rats (7) , there have been no subsequent confirmation studies. In a recent study, however, the liver weight and mitotic index of hepatocytes were significantly increased in male Wistar rats following a single treatment with NDBzA (8) . In this two stage cancer study, in which NDBzA (10 mg/kg) was given twice a week for 23 weeks after an initiation treatment with N-nitrosodiethylamine (2ϫ100 mg/kg), the number and size of preneoplastic liver cell foci were significantly increased, but not following an initiation treatment with 2-acetylaminofluorene (2ϫ150 mg/kg). The possibility of NDBzA being a complete carcinogen, however, cannot be excluded, since treatment with NDBzA alone was not included in this experiment.
The mutagenicity of NDBzA has been reported in many studies. A negative response in Salmonella was reported in early studies using standard concentrations of S9 (9, 10) . Subsequent in vitro studies, however, obtained positive responses using more optimal (i.e. higher) concentrations of S9 for metabolic activation (5, 11, 12) . When the level of S9 was increased from 10 to 20 or 30%, NDBzA gave positive responses in strains TA100 and TA98 (12) . Gene mutation to 6-thioguanine resistance was detected when V79 cells were treated in vitro with up to 25 µg/ml NDBzA, but only with liver S9 from Aroclor-induced and uninduced hamsters (5) . An increase in sister chromatid exchange (SCE) frequency was seen only at 25 µg/ml NDBzA in the presence of uninduced hamster hepatocytes in this study. However, another study indicated that NDBzA can induce micronuclei and single strand breaks (SSB) in rat and hamster hepatocytes in vitro (13) . The induction of SSB and micronuclei in vivo was reported in rat liver (12, 14) . The induction of micronuclei, however, was not seen in either rat or mouse bone marrow (12) . These results demonstrate that NDBzA induces gene mutation and chromosome breakage in vitro and chromosome breakage in vivo, but the ability of this compound to induce gene mutation in vivo remains to be elucidated.
Transgenic mouse systems have been shown to be useful for studying gene mutation in vivo (15) (16) (17) (18) . This is largely attributed to their ability to detect tissue-specific gene mutations. For example, NDMA was shown to induce gene mutation in the transgenic mouse liver (19) (20) (21) . Similarly, N-nitrosodiethylamine (NDEA) has also been shown to induce mutation in mouse liver, but not in bone marrow (22) . Since NDBzA is a structural analog of NDMA and NDEA, these studies, together with in vivo liver and bone marrow micronucleus results (12) , suggest that NDBzA may have similar tissue specificity for induction of gene mutation detectable using a transgenic mouse assay. Accordingly, we have studied the induction of gene mutations by NDBzA in both liver and bone marrow. The molecular characteristics of liver mutants induced by NDBzA were also analysed by DNA sequencing in order to elucidate the possible mechanism of mutation induction. 
Materials and methods

Animal treatment
The lacZ transgenic Muta™Mouse strain (40.6) used has been described in detail elsewhere (15, 18, 23, 24 (25) . The identity and purity (Ͼ99%) of NDBzA was confirmed by mass spectrometry (W.Fiddler, personal communication). After being suspended in olive oil, NDBzA was administered orally once to five male mice at each dose (30, 100, 435 and 750 mg/kg). Three single doses (2, 6 and 10 mg/kg) of NDMA were also included as positive controls. The negative control mice were given olive oil only. Tissue collection and DNA isolation Since mutation fixation times Ͼ30 days are indicated for liver (30) and fixation times up to 30 days are adequate for bone marrow (30) , animals were killed by cervical dislocation 30 and 90 days after treatment. Bone marrow was collected by flushing the femurs with phosphate-buffered saline (PBS) and a cell pellet obtained. Livers were removed immediately and placed in storage vials. Both bone marrow cells and liver tissues were frozen in liquid nitrogen and stored at -80°C until used. After thawing, DNA was extracted as described previously (24) . Briefly, isolation from the liver was performed by homogenizing the tissues in TMST buffer (50 mM Tris, pH 7.6, 3 mM magnesium acetate, 250 mM sucrose and 0.2% Triton X-100), followed by digestion with proteinase K (1 mg/ml) and 0.2% SDS overnight at 37°C in lysis buffer (10 mM Tris, pH 7.6, 150 mM NaCl and 10 mM EDTA). Bone marrow cells were suspended in the lysis buffer and digested overnight at 37-40°C in 0.2% SDS with 1 mg/ml proteinase K dissolved in lysis buffer. DNA was then extracted with phenol/chloroform and precipitated with absolute ethanol. Mutant rescue and characterization lacZ mutants were rescued with commercial packaging extract (Gigapack II Gold; Stratagene, CA) under conditions recommended by the manufacturer. The lacZ mutants were selected using a positive selection system (18, 24, (26) (27) (28) . Briefly, phage particles were adsorbed to Escherichia coli C lac -galEhost cells and selected for growth on LB/saline minimal agar plates containing 0.3% phenyl β-D-galactoside (P-gal; Sigma Chemical Co., MO). Mutant plaques were picked randomly from plates after overnight incubation at 37°C and scored. The phage titre was determined by plating a small portion of the phage/cell mixture on LB/saline minimal top agar without P-gal.
Mutants to be sequenced (no more than 4/plate) were confirmed by replating them onto LB/5-bromo-4-chloro-3-indolyl-β-D-galactoside plates and then putatively localized to one of three complementation regions (α, β or ω) 2240 according to a protein complementation assay (18, 23, 24) . The sequence fragment corresponding to the appropriate complementation region was amplified (GeneAmp@ PCR kit; Perkin Elmer Co., CA) and purified using a PCR purification kit (Promega Co., WI). The purified PCR products were sequenced using an automatic DNA Sequencer (ABI 377; Perkin Elmer Co., CA) and analysed using Sequence Navigator software (Perkin Elmer Co., CA).
Results
Mutagenic potency of NDBzA
To detect the lacZ mutations induced in both liver and bone marrow~1.5ϫ10 6 -4.5ϫ10 6 p.f.u. from each treatment group were plated. The frequency of lacZ mutations detected after exposure to either NDBzA or NDMA in these two tissues is reported in Tables I and II . After NDMA treatment the increases in mutant frequencies in liver were clearly dose dependent (Table I and Figure 1 , inset) and were comparable with published results (19) (20) (21) . A dose-dependent increase in mutant frequency was also observed in both 30 and 90 day NDBzAtreated liver samples (Table II and Figure 1 ). No increases, however, were seen in bone marrow at either time point following either NDBzA or NDMA treatment (Table II) .
Although the responses appear somewhat curvilinear, curve fitting analysis (GraphPad Prism™ software) revealed that statistically each of the four dose-response curves in Figure 1 could be represented by a straight line. The slopes of the linear regression lines for NDBzA 30 and 90 days post-treatment are 1.536 Ϯ 0.31 and 2.134 Ϯ 0.237 respectively and for NDMA at 30 and 90 days 0.0129 Ϯ 0.0024 and 0.0123 Ϯ 0.0018. Accordingly, in as much as the data represent actual mutant frequencies, NDBzA is 119 (i.e. 1.536/0.0129) to 174 (i.e. 2.134/0.0123) times less mutagenic than NDMA in mouse liver. The mutant frequencies obtained 30 and 90 days after treatment with either NDMA or NDBzA were comparable, indicating that potential mutagenic effects at the dose used were reached by day 30 and did not decline within the subsequent 60 days. This observation lends support to the hypothesis that a single sampling time may be suitable in transgenic rodent mutation studies (29, 30) .
Molecular characterization of the lacZ mutants
To analyse the nature of the lacZ mutants induced we sequenced a total of 81 NDBzA-induced liver mutants, picked randomly Tables III and IV  and summarized in Table V (Tables III and IV) .
Site specificity of mutations
Site specificity analysis of mutations induced by NDBzA indicates that the base substitutions were not randomly distributed. While the majority of spontaneous G:C→A:T mutations have been detected at 5Ј-CpG-3Ј sites (18, 30) , many fewer such events were detected in the present study in samples from NDBzA-treated mice taken 30 and 90 days after treatment.
The most significant increase in mutation type was seen in G:C→T:A transversions, which were increased from 8.9% in spontaneous (30) to 39.2% in 30 and 16.7% in 90 day samples. Further analysis indicated that a major portion of G:C→T:A transversions were detected at 5Ј-CpG-3Ј sites in both 30 (50%) and 90 day (60%) samples. G:C→T:A transversions were also preferentially detected at dipurine or dipyrimidine sites among NDBzA-induced mutants; such prevalence being more obvious in 30 day than in 90 day samples.
Discussion
Differences in metabolism are one of the major reasons for tissue-specific mutagenesis after chemical treatment. As expected, like its analog NDMA (22) , NDBzA induced an increase in mutant frequency in liver, but not bone marrow (Figure 1) , because of an apparent tissue difference in metabolism or physiology (12) . It has been suggested that NDBzA is metabolically activated through α-hydroxylation, resulting in an unstable intermediate (12, 31) . Consequently, loss of the hydrolysed benzyl group, in the form of a benzaldehyde, leads to formation of DNA benzylating species, which may have mutagenic potential. Evidence supporting this speculation comes from analogues such as N-nitrosomethyl-benzylamine (NMBzA), NDMA and N-nitroso-α-acetoxybenzyl-benzylamine; each has the potential to benzylate and/or methylate DNA (31) . The benzylating species formed by NDBzA may attack DNA and form bulky DNA adducts, likely involving adenosine and/or guanosine. N-Nitrosobenzylurea, a benzylating compound, was shown to interact with adenosine and guanosine in vitro, leading to formation of exocyclic as well as endocyclic benzylation products (32) . The mutagenic potential of these benzylated DNA adducts, however, remains relatively unknown. Adducts such as O 6 -methylguanine have been linked to the mutagenesis of both NMBzA and NDMA (33, 34) .
The significance of O 6 -benzylguanine (O 6 -benzylG) in the mutagenesis of NDBzA, however, is not clear. It has been suggested that O 6 -benzylG may exert its mutagenic potential through semi-targeted as well as targeted pathways (35) . O 6 -BenzylG may induce transitions and/or transversions depending on the surrounding sequence content (35, 36) . When incorporated at the second guanine position in a 5Ј-GGA-3Ј sequence (H-ras codon 12), O 6 -benzylG induced G→A, G→T and G→C mutations, but induced exclusively G→A mutations when 2242 incorporated at the first guanine position. Results from this study appear to be consistent with this suggestion. There were seven G:C→T:A, two G:C→C:A transversions and three G:C→A:T transitions detected at the second G in the 5Ј-GG-3Ј sequence in the 30 day spectrum (Table III) . This tendency was also observed in the 90 day spectrum, albeit less significantly. Nevertheless, the rapid and efficient depletion of O 6 -alkylguanine alkyltransferase by benzylated adducts (36, 37) could also play a role in the type of mutation generated, likely through enhancing endogenous mutagenic intermediates, which are normally repaired by this enzyme. In addition, the oxygen free radicals generated during NDBzA metabolism may also play a role by inhibiting cellular DNA repair (38) and by inducing mutations such as G→T transversion (39). 8-Hydroxyguanine, an important oxidated DNA adduct, has been shown to induce preferentially G→T transversions (40) . Further analysis indicates that a significant portion (50 and 60% respectively) of G:C→T:A transversions was detected at 2243 5Ј-CpG-3Ј sites after NDBzA treatment (Table V) . The detection of transversions preferentially at this dinucleotide site is likely to be linked to hypermethylation of this transgene in vivo (16) . 5-Methylcytosine (5-meC) may induce G:C→T:A changes by an unknown pathway that yields mostly 5-meC→A transversions (41) . Alternatively, transversion at this site could be a result of inhibition of repair of a guanine adduct on the opposite strand by methylated cytosine (42) . In contrast, the origin of G:C→C:G transversions is much less clear; their occurrence may be linked to either bulky O 6 -benzylG DNA adducts or enhanced mutagenic potential of some adducts by 5-meC, since two of the six G:C→C:G changes occurred at 5Ј-CpG-3Ј sites.
G:C→A:T transitions were detected in all mutational spectra (Table V) . The primary mechanism for the aetiology of these G:C→A:T transitions is likely deamination of 5-meC, leading to formation of thymine, since a significant number of mutations were detected at 5Ј-CpG-3Ј sites. The recovery of this mutation at non-CpG sites after NDBzA treatment may be caused by O 6 -benzylG, which also produce G→A transitions (35, 36) . In fact, a significant number of G:C→A:T transitions (10/18 and 5/12 respectively) were detected at 5Ј-GG-3Ј sites, a characteristic not seen in the spontaneous spectrum (18, 30) . In addition, G:C→A:T transitions may arise from either unspecified mutagenic intermediates or apurinic (AP) sites formed when bulky guanosine adducts are repaired by apurinic endonucleases. The production of single strand breaks after NDBzA treatment supports speculation regarding a role for AP sites (43) .
In this study we have characterized lacZ mutants detected 30 and 90 days following NDBzA treatment in transgenic mouse liver. Molecular analysis of a total of 81 lacZ mutants after NDBzA treatment indicates that mutations detected at both time points had similar characteristics and were different from spontaneous mutations, which exhibit a preponderance of G:C→A:T transitions, mainly at 5Ј-CpG-3Ј sites (30) . The predominant recovery of G:C→T:A transversions in 30 and 90 day samples indicates that these mutations may originate from bulky DNA adducts, such as O 6 -benzylG, however, other pathways may also contribute. We conclude that NDBzA induces gene mutation in vivo, likely via bulky DNA adducts. It is, however, a relatively less potent mutagen than NDMA. Mutant frequencies, as well as spectra, detected at both time points were very similar, suggesting that the processes leading to the formation of mutations from 0-30 and 30-90 days posttreatment were also similar.
